Valuation: Shield Therapeutics plc

Market Cap 55.64M 74.22M 65.97M 61.15M 105M 7.04B 107M 735M 288M 3.68B 279M 273M 11.72B P/E 2026 *
347x
P/E 2027 * 7.01x
Enterprise Value 74.09M 98.84M 87.86M 81.43M 140M 9.38B 142M 979M 384M 4.9B 371M 363M 15.6B EV / Sales 2026 *
1.39x
EV / Sales 2027 * 1.05x
Free-Float
38.49%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Shield Therapeutics plc

1 week-1.89%
Current month-13.62%
1 month+14.29%
3 months-16.80%
6 months-43.48%
Current year-47.21%
1 week 5.05
Extreme 5.052
5.4
1 month 4.6
Extreme 4.6
6.1
Current year 3.7
Extreme 3.7
12.5
1 year 3.7
Extreme 3.7
12.5
3 years 1.06
Extreme 1.0625
12.5
5 years 1.06
Extreme 1.0625
52
10 years 1.06
Extreme 1.0625
202
Manager TitleAgeSince
Chief Executive Officer 64 23/07/2024
Director of Finance/CFO 50 31/08/2026
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 68 31/01/2016
Chairman 70 17/06/2020
Director/Board Member 59 25/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
14/10/25 Free

Chief Executive Officer

1,547,262 0.1485%
13/02/25 Free

Chief Executive Officer

5,000,000 0.4800%
13/02/25 Buy

Chief Executive Officer

575,000 0.0552%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-1.89%-33.76%-14.05% 74.22M
+0.43%+6.59%+53.41%+103.85% 1,120B
+0.90%-2.25%+33.02%+62.23% 616B
+0.71%+3.24%+25.81%+93.86% 504B
-0.13%+5.98%+32.91%+50.39% 367B
+0.52%+0.24%+73.92%+40.15% 360B
-0.95%+4.70%+19.51%+43.00% 288B
-1.98%+3.73%-0.86%+13.43% 258B
-0.35%+4.25%+46.21%+50.76% 234B
-0.75%+3.32%+32.53%+97.21% 194B
Average -0.16%+3.06%+28.27%+54.08% 394.1B
Weighted average by Cap. +0.13%+3.83%+39.18%+71.43%

Financials

2026 *2027 *
Net sales 53.48M 71.35M 63.42M 58.78M 101M 6.77B 103M 707M 277M 3.53B 268M 262M 11.26B 69.92M 93.27M 82.91M 76.85M 132M 8.85B 134M 924M 362M 4.62B 350M 343M 14.73B
Net income 258K 344K 306K 284K 487K 32.67M 495K 3.41M 1.34M 17.05M 1.29M 1.26M 54.34M 7.74M 10.33M 9.18M 8.51M 14.61M 980M 14.85M 102M 40.11M 512M 38.77M 37.94M 1.63B
Net Debt 18.45M 24.62M 21.88M 20.28M 34.82M 2.34B 35.38M 244M 95.58M 1.22B 92.39M 90.42M 3.89B 18M 24.01M 21.34M 19.78M 33.96M 2.28B 34.51M 238M 93.23M 1.19B 90.11M 88.19M 3.79B
Projected Income Statement - Annual - Shield Therapeutics plc
Logo Shield Therapeutics plc
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Employees
61
Date Price Change Volume
16/10/26 GBX 5.200 0.00% 590,860
15/10/26 GBX 5.200 -0.95% 710,556
14/10/26 GBX 5.250 0.00% 213,812
13/10/26 GBX 5.250 0.00% 666,007
12/10/26 GBX 5.250 -0.94% 745,052
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Shield Therapeutics plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0520GBP
Average target price
0.1667GBP
Spread / Average Target
+220.52%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Shield Therapeutics plc